Maribavir for CMV after stem cell transplant
Treatments studied
Part of Infections clinical trials.
This study tests a medicine called maribavir for people who have a CMV infection after a stem cell transplant. It watches how well the medicine works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult who has had a stem cell transplant.
- You must have a confirmed CMV infection (in your blood or as an illness).
- You must be expected to live at least 4 weeks.
- You cannot be in another CMV study right now.
- Your liver function must be within a safe range (no severe liver problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This trial tests whether taking maribavir for different lengths of time can help treat a stubborn CMV infection after a stem cell transplant. It is for people whose CMV hasn't improved with standard treatment.
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
This study tests a new medicine called maribavir for Chinese adults who have a CMV infection that hasn't gotten better with standard treatments. It may be an option for transplant recipients who need a different approach.
This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.
Hear when a new Infections, Cytomegalovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.